<DOC>
	<DOCNO>NCT01395914</DOCNO>
	<brief_summary>The administration Anamorelin HCl patient Non-Small Cell Lung Cancer-Cachexia ( NSCLC-C ) expect increase appetite , lean body mass , weight gain , muscle strength .</brief_summary>
	<brief_title>Anamorelin HCl Treatment Non-Small Cell Lung Cancer-Cachexia ( NSCLC-C ) : An Extension Study ( ROMANA 3 )</brief_title>
	<detailed_description>This randomize , double-blind , parallel-group , placebo-controlled , extension study assess safety efficacy Anamorelin HCl NSCLC-C patient .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<criteria>Has complete Day 85 Visit original trial ( Study HTANAM301 HTANAM302 ) consider appropriate continue receive additional study drug ; must start dose extension study within 5 day complete dose original trial ECOG performance status â‰¤2 Life expectancy &gt; 4 month time screen If woman childbearing potential fertile man , he/she must agree use effective form contraception study 30 day follow last dose study drug ( effective form contraception abstinence , hormonal contraceptive , doublebarrier method ) Must willing able give sign informed consent , opinion Investigator , comply protocol test procedure Women pregnant breastfeeding Had major surgery ( central venous access placement tumor biopsy consider major surgery ) within 4 week prior enrollment extension study ; patient must well recover acute effect surgery prior screen ; patient plan undergo major surgical procedure treatment period Currently take prescription medication intend increase appetite treat weight loss ; include , limited , testosterone , androgenic compound , megestrol acetate , methylphenidate , dronabinol Inability readily swallow oral tablet ; patient severe gastrointestinal disease ( include esophagitis , gastritis , malabsorption , obstructive symptom ) intractable frequent vomiting exclude Has active , uncontrolled infection Has know symptomatic brain metastasis Receiving strong CYP3A4 inhibitor Receiving tube feeding parenteral nutrition ( either total partial ) ; patient must discontinue treatment least 6 week prior Day 1 , throughout study duration Other clinical diagnosis , ongoing intercurrent illness Investigator 's opinion would prevent patient 's participation Patients actively receive concurrent investigational agent , Anamorelin HCl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>